Pseudomonas aeruginosa: Combined treatment vs. monotherapy;Pseudomonas aeruginosa: Tratamiento combinado frente a monoterapia

Medicina Intensiva

Volumn 31, Issue 2, 2007, Pages 83-87

  Bodi M ^a   Garnacho, Y J ^b  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Combination therapy; Microbiological results; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC;

ANTIBIOTIC THERAPY; BACTEREMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; GRAM NEGATIVE INFECTION; HUMAN; INFECTION RISK; META ANALYSIS; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MORBIDITY; MORTALITY; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; SYSTEMATIC REVIEW;

EID: 34247474398     PISSN: 02105691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-5691(07)74780-0     Document Type: Article

References (28)

1. Álvarez F, Palomar M, Olaechea P, Insausti J, Bermejo B, Cerdá E, et al. Estudio nacional de vigilancia de infección nosocomial en unidades de cuidados intensivos. Informe del año 2002. Med Intensiva. 2005;29:1-12.
2. Bodí M, Rodríguez A, Solé-Violán J, Gilavert MC, Garnacho J, Blanquer J and CAPUCI Study Investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005;41:1709-16.
3. Cheol-In K, Sung-Han K, Hong-Bin K, Sang-Won P, Young-Ju Ch, Myoung-don O, et al. Pseudomonas aeruginosa bacteriemia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37:745-51.
4. Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis. 2000;19:915-25.
5. Vidal F, Mensa J, Almela M, Martínez JA, Marco F, Casals C, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 1996;156: 2121-6.
6. Rello J, Jubert P, Vallés J, Artigas A, Rue M, Niederman MS, Reichley RM, Fraser VJ, Kollef MH, et al. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis. 1996;23:973-8.
7. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634-40.
8. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med. 2001;29 Suppl 4:N114-20.
9. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore MH, Carmeli Y. Epidemiology and clinical outcomes of patients with multirresistant Pseudomonas aeruginosa. Clin Infect Dis. 1999;28:1128-33.
10. McCabe WR, Jackson GG. Gram negative bacteremia. Arch Intern Med. 1962;110:92-100.
11. Garnacho-Montero J, García-Garmendia JL, Barrero-Almodóvar A, Jiménez-Jiménez FJ, Pérez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31:2742-51.
12. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115:529-35.
13. McGrath BJ, Lamp KC, Rybak MJ. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother. 1993;37:1931-7.
14. Cappelletty DM. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model. Antimicrob Agents Chemother. 1999;43:129-33.
15. Piccoli L, Guerrini M, Felici A, Marchetti F. In vitro and in vivo synergy of levofloxacin ir amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa. J Chemother. 2005;17:355-60.
16. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87:540-6.
17. Chatzinikolau I, Abi-Sad D, Bodey GP, Rolston KV, Tarraud JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med. 2000;160:501-19.
18. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteremia? A meta-analysis. Lancet Infect Dis. 2004;4:519-27.
19. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlation in a prospective study of 200 patients. Am J Med. 1989;87:540-6.
20. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 1998;17:701-8.
21. Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteremia. Lancet Infect Dis. 2005;5: 192-3.
22. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328:668-82.
23. Chamot E, El Amari EB, Rohner P, Van Delden Ch. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2003;47: 2756-64.
24. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379-82.
25. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001;134:298-314.
26. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146-55.
27. Micek ST, Lyoyds AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49: 1306-11.
28. Rello J, Ausina V, Ricart M, Puzo C, Quintana E, Net A. Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator- associated pneumonia. Intensive Care Med. 1994; 20:193-8.